Repatha vs Leqvio Head-to-Head Efficacy: Evolocumab vs Inclisiran Compared

Why Comparing Repatha and Leqvio Requires More Than an LDL Number

On the surface, the two drugs look nearly identical: each cuts LDL cholesterol by roughly 50% added to statin therapy, each targets the PCSK9 protein, and each is injectable. The comparison gets interesting once you look at mechanism, dosing frequency, who administers the injection, and what the cardiovascular outcomes data actually prove right now.

Clinicians at HealthRX evaluate both agents for patients with familial hypercholesterolemia (FH), established atherosclerotic cardiovascular disease (ASCVD), or statin intolerance. The decision is rarely simple. Below is the clinical evidence, organized by the questions that matter most at the prescribing level.

Mechanism of Action: Same Target, Different Biology

How Repatha (Evolocumab) Works

Evolocumab is a fully human monoclonal antibody (IgG2) that binds PCSK9 protein directly in the bloodstream. By blocking PCSK9 from degrading LDL receptors on hepatocytes, more receptors remain on the liver cell surface, and circulating LDL is cleared faster. Peak plasma inhibition occurs within hours of each injection, then gradually wanes until the next dose.

How Leqvio (Inclisiran) Works

Inclisiran is a small interfering RNA (siRNA) conjugated to GalNAc (N-acetylgalactosamine), which targets the drug specifically to hepatocytes. Once inside the cell, it silences the PCSK9 gene itself, so the liver produces far less PCSK9 protein to begin with. Because the silencing effect persists at the intracellular level, a single injection sustains LDL lowering for approximately six months. This is why dosing is twice yearly after two loading doses.

Clinical Implication of the Mechanistic Difference

The downstream LDL result is similar, but the durability profile differs sharply. Evolocumab's effect wanes between doses; inclisiran's effect is far more durable because it addresses PCSK9 production rather than circulating protein. For patients with documented poor injection adherence, inclisiran's twice-yearly clinician-administered schedule may provide more consistent LDL suppression over time.

LDL-C Efficacy: What the Trials Actually Show

FOURIER Trial (Repatha)

The FOURIER trial enrolled 27,564 patients with established ASCVD already receiving statin therapy. Evolocumab 140 mg every two weeks or 420 mg monthly produced a mean LDL-C reduction of 59% from baseline at 48 weeks (from a median baseline of 92 mg/dL down to 30 mg/dL), compared with a 0% change in the placebo group [1]. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [1].

That 15% relative MACE reduction is the benchmark every PCSK9 inhibitor is measured against. The absolute risk reduction was 1.5 percentage points over the trial period.

ORION-10 and ORION-11 Trials (Leqvio)

ORION-10 enrolled 1,561 patients in the United States with ASCVD on maximally tolerated statin therapy. ORION-11 enrolled 1,617 patients in Europe and South Africa with ASCVD or high-risk primary prevention. In both trials, inclisiran 284 mg produced approximately 50% time-averaged LDL-C reduction from baseline across the dosing interval, compared with placebo [2]. Specifically:

• ORION-10: LDL-C reduction of 52.3% at day 510 (P<0.001 vs. Placebo)
• ORION-11: LDL-C reduction of 49.9% at day 510 (P<0.001 vs. Placebo)

The time-averaged analysis matters here because inclisiran's LDL effect is sustained across the six-month dosing window, whereas a trough measurement before the next evolocumab injection would show some rebound.

Comparing LDL Numbers Across Trials

No randomized head-to-head trial has directly compared evolocumab and inclisiran for LDL-C reduction or cardiovascular outcomes as of July 2025. The approximately 50% figure applies to both agents in their respective trials, but differences in trial populations, baseline LDL levels, and statin intensity make cross-trial comparisons imperfect. What the data do support is that both drugs reliably achieve LDL levels well below 70 mg/dL (and often below 50 mg/dL) in patients on background statin therapy.

Cardiovascular Outcomes: A Key Asymmetry

This is the most clinically significant difference between the two drugs right now.

Repatha Has Proven MACE Reduction

FOURIER demonstrated a statistically significant 15% reduction in a five-component MACE composite [1]. The GLAGOV trial (N=968) also showed that evolocumab produced significant coronary plaque regression versus placebo at 78 weeks, assessed by intravascular ultrasound [3].

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy, adding a PCSK9 inhibitor is reasonable (Class IIa, Level of Evidence A)" [4]. Evolocumab is explicitly cited as an agent with outcomes data supporting this recommendation.

Leqvio's Outcomes Data Are Pending

ORION-4, the cardiovascular outcomes trial for inclisiran, enrolled 15,000 high-cardiovascular-risk patients and is expected to report primary results around 2026. Until that data is published and peer-reviewed, inclisiran's MACE benefit is inferred from its LDL-lowering magnitude (using the Mendelian randomization and statin meta-analysis principle that each 1 mmol/L LDL reduction reduces major vascular events by approximately 22%) rather than directly proven [5].

For a cardiologist managing a patient who just survived an MI, the absence of direct outcomes data for inclisiran is a real clinical consideration, not a technicality.

Dosing, Administration, and Adherence

Repatha Dosing Schedule

Evolocumab is available as a prefilled autoinjector (SureClick) or prefilled syringe, 140 mg/mL. Patients self-inject subcutaneously every two weeks (140 mg) or once monthly (420 mg as three consecutive injections or via a prefilled cartridge device). Administration is at home; no office visit required per dose.

The practical consequence: over one year, a patient on the biweekly schedule makes 26 injections. On the monthly schedule, that drops to 12. Both schedules require the patient to remember and execute the injection independently.

Leqvio Dosing Schedule

Inclisiran is given as a single 284 mg subcutaneous injection at day 1, again at three months (day 90), and then every six months thereafter. The injection is administered by a healthcare professional in a clinical setting. After the second dose, patients receive only two injections per year.

The clinician-administration model eliminates self-injection adherence failures entirely. A 2023 real-world analysis of European cardiology practices found that patient-administered PCSK9 inhibitor discontinuation rates at 12 months ranged from 30% to 40%, compared with near-100% adherence for clinician-administered inclisiran when scheduled as a routine office procedure [6].

Which Dosing Schedule Fits Which Patient?

The HealthRX clinical team uses the following decision framework when choosing between evolocumab and inclisiran:

Choose evolocumab (Repatha) when:

• The patient has established ASCVD and you want the backing of direct MACE outcome data today
• The patient is comfortable with home self-injection and has a track record of medication adherence
• Rapid LDL lowering within days is needed (post-ACS, aggressive risk reduction goal)
• The patient cannot reliably attend biannual clinic appointments

Choose inclisiran (Leqvio) when:

• Poor adherence to self-injected medications has been documented in the chart
• The patient prefers to have injections administered by a nurse or physician
• Simplifying the medication burden is a therapeutic goal (two injections per year fits naturally into routine cardiology follow-up)
• The patient has FH and has maintained high LDL despite multiple prior regimens

Safety Profiles

Repatha Safety Data (FOURIER and Post-Marketing)

In FOURIER, the most common adverse events with evolocumab were injection-site reactions (2.1% vs. 1.6% placebo), nasopharyngitis, and upper respiratory tract infection [1]. Neurocognitive adverse events were evaluated prospectively in the EBBINGHAUS sub-study (N=1,204): no significant difference in cognitive function was found between evolocumab and placebo over approximately 19 months [7]. Evolocumab does not appear to cause new-onset diabetes at the rates seen with statins.

Leqvio Safety Data (ORION Pooled Analysis)

Across the ORION phase 3 program, inclisiran's safety profile was similarly favorable. Injection-site reactions occurred in 2.6% of inclisiran recipients vs. 0.9% placebo in pooled analysis [2]. No significant increases in liver enzyme elevations, renal toxicity, or thrombocytopenia were observed. Because inclisiran is hepatocyte-targeted via GalNAc conjugation, off-target siRNA effects in other tissues appear minimal based on current data.

Shared Contraindications and Cautions

Neither drug is approved in pregnancy. Both require monitoring for hypersensitivity reactions, though these are uncommon. Patients with severe hepatic impairment have limited data for both agents. Renal impairment does not appear to significantly alter evolocumab pharmacokinetics; inclisiran dose adjustment guidance in severe renal impairment (eGFR <30 mL/min/1.73m2) is based on limited data and warrants caution.

FDA Approvals and Labeled Indications

Repatha (evolocumab) received FDA approval in August 2015 for adults with primary hyperlipidemia (including HeFH), and received a cardiovascular risk reduction indication in December 2017 following FOURIER [8]. It is also approved for homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients aged 10 and older.

Leqvio (inclisiran) received FDA approval in December 2021 for adults with primary hyperlipidemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy [9]. As of July 2025, inclisiran does not carry an FDA-approved cardiovascular risk reduction indication independent of its LDL-lowering indication.

Cost, Coverage, and Access

Both drugs carry list prices exceeding $6,000 per year in the United States, making insurance prior authorization the practical bottleneck. Commercial payers typically require documented LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe before approving either agent. Medicare Part B covers inclisiran as a physician-administered drug (J-code billing), which can simplify reimbursement in the Medicare population compared with the Part D pharmacy benefit pathway for evolocumab.

Amgen's Repatha Copay Card program can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. Novartis offers the Leqvio Ready program with similar patient assistance. Patients without insurance should contact each manufacturer directly; both companies operate indigent access programs.

Switching From Repatha to Leqvio (or Vice Versa)

Switching between evolocumab and inclisiran is clinically feasible and is being done in practice as inclisiran becomes more widely available. No pharmacokinetic interaction exists between the two agents. The practical approach:

1. Confirm LDL-C on the current agent and document the value.
2. Discontinue evolocumab. Because inclisiran's first three-month loading sequence is needed to establish sustained LDL suppression, begin inclisiran's day-1 injection promptly to minimize LDL rebound.
3. Repeat LDL-C at three months after the second inclisiran dose to confirm adequate response.
4. Switching in the opposite direction (inclisiran to evolocumab) can be done at any time; evolocumab reaches maximal effect within one to two weeks of the first injection.

The 2023 European Atherosclerosis Society consensus on PCSK9 inhibitor therapy notes that switching between PCSK9-targeting agents is acceptable when driven by adherence concerns, tolerability, or access issues, provided LDL monitoring continues after the transition [10].

What the Evidence Does Not Yet Tell Us

Several clinically meaningful questions remain unanswered as of mid-2025:

• Direct head-to-head MACE comparison. No randomized trial has enrolled patients to evolocumab versus inclisiran with cardiovascular events as the primary endpoint.
• Long-term safety beyond five years. FOURIER had a median follow-up of 2.2 years. ORION trials are longer in follow-up but not yet complete.
• Combination or sequential therapy. Whether combining a PCSK9 antibody with a PCSK9 siRNA (or sequencing them) offers additive benefit is not established.
• Outcomes in HoFH. Inclisiran's effect in homozygous FH is attenuated because the silencing of PCSK9 expression depends on some baseline PCSK9 production; patients with loss-of-function LDLR mutations respond less robustly.

Clinical Bottom Line: How to Choose

The LDL-lowering efficacy of Repatha and Leqvio is comparable at approximately 50% reduction on background statin therapy. The differences that drive the prescribing decision are:

• Outcomes data: Repatha has it. Leqvio does not yet.
• Dosing burden: Leqvio wins on frequency (2 injections per year vs. 12 to 26).
• Administration: Leqvio requires an office visit; Repatha does not.
• Adherence risk: Leqvio eliminates self-injection failure by design.
• HoFH: Repatha is preferred; inclisiran has attenuated efficacy in this population.
• Medicare Part B billing: Leqvio may be simpler to access for older patients.

For a 58-year-old post-MI patient with LDL-C of 95 mg/dL on high-intensity rosuvastatin plus ezetimibe, the ACC/AHA Class IIa recommendation supports adding a PCSK9 inhibitor with outcomes data. Evolocumab fits that profile today. For a 62-year-old with FH and a documented history of skipping biweekly injections, inclisiran's twice-yearly clinic-administered schedule may deliver more consistent LDL lowering in practice, even without the outcomes label.